William Kevin Kelly, DO
Articles
Dr. Kelly on Radium-223 Dichloride and Niraparib in Patients With mCRPC
June 9th 2020William K. Kelly, DO, discusses results from a phase 1b dose-finding study (NCT03076203) evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.
Read More
Dr. Kelly on the Rationale for Combining Radium-223 and Niraparib in mCRPC
June 5th 2020William Kevin Kelly, DO, discusses the rationale for a phase 1b dose-finding study evaluating the combination radium-223 dichloride and niraparib in patients with metastatic castration-resistant prostate cancer.
Read More
Dr. Kelly on the Importance of Local Control in Locally Advanced Prostate Cancer
April 10th 2018William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, director, Division of the Solid Tumor Oncology, Sidney Kimmel Cancer Center, discusses the evolution of local control in locally advanced prostate cancer.
Read More
Dr. Kelly on Selecting Therapy for Patients with CRPC
November 27th 2013William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.
Read More
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
